Personalis SEC Filings

Personalis, Inc. announced that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has revised its Medicare reimbursement rates for the company’s ultrasensitive NeXT Personal® test used to monitor cancer recurrence in stage II and III breast cancer patients. Effective December 1, 2025, the NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be reimbursed at $4,266 and the NeXT Personal Single Plasma Test at $1,164. Medicare will cover the Dx Breast MRD Recurrence Monitoring Test once per cancer diagnosis, while the Single Plasma Test is covered for up to six years after treatment, shaping how often these tests can be used for long-term patient surveillance.

Personalis (PSNL) announced that its ultrasensitive NeXT Personal tests received Medicare coverage for post‑treatment surveillance of cancer recurrence in stage II and III breast cancer. The determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program is effective retroactively as of October 7, 2025.

The NeXT Personal Dx Breast MRD Recurrence Monitoring Test is covered at a reimbursement rate of $3,878 and is available once per cancer diagnosis. The NeXT Personal Single Plasma Test is covered at $1,158 and is available for up to six years post‑treatment. This expands access and establishes defined payment levels for these assays among eligible Medicare patients.

Personalis, Inc. (PSNL) reported an insider transaction by its President and CEO. On 11/03/2025, the reporting person sold 29,612 shares of common stock at a weighted average price of $8.99, with individual sale prices ranging from $8.78 to $9.56. The filing states the shares were automatically sold to cover tax withholding from the settlement of vested restricted stock units. Following the transaction, the reporting person beneficially owned 148,486 shares directly.

Personalis, Inc. reported Q3 results and liquidity updates. Revenue was $14.5M for the quarter, down from $25.7M a year ago, reflecting lower enterprise and population sequencing activity. Pharma tests and services contributed $13.1M. The company posted a net loss of $21.7M versus a prior-year net loss of $39.1M, which previously included a large noncash warrant fair value charge.

Year‑to‑date revenue was $52.3M versus $67.8M last year, with operating cash use of $52.7M. Cash and cash equivalents were $50.0M and short‑term investments were $100.5M as of September 30, 2025. Shares outstanding were 88,804,348 as of October 28, 2025. During the nine months, the company raised $17.8M net via its ATM program.

Customer concentration remained significant, including contributions from Moderna, Regeneron and Pfizer in the period. The Tempus commercialization agreement continued, with $6.0M in market development fees received and amortizing against promotional costs.

Personalis, Inc. (PSNL) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025.

The full text of the release is provided as Exhibit 99.1 and is incorporated herein by reference. The information, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other Securities Act or Exchange Act filings except as expressly set forth by specific reference.

Amendment No. 2 to a Schedule 13D reports that Tempus AI, Inc. beneficially holds 12,718,800 shares of Personalis common stock, representing 14.3% of the outstanding shares based on 88,677,062 shares outstanding. Tempus acquired 9,218,800 shares by exercising warrants for $18,437,600 and purchased 3,500,000 shares from the issuer at $5.07 per share, funded from working capital.

The filing notes that Eric Lefkofsky, as controlling stockholder of Tempus, may be deemed to beneficially own the Tempus-held shares and directly holds 150,000 additional shares, bringing his aggregate to 12,868,800 shares (about 14.5%). The parties amended their Commercialization Agreement to permit Tempus to make open-market purchases up to 19.99% provided other standstill terms are met. A copy of Amendment No. 5 is filed as an exhibit.

Personalis, Inc. (PSNL) filed a Form S-8 to register 350,000 additional common shares (par $0.0001) for issuance under its 2020 Inducement Plan. The filing, made on 5 Aug 2025, brings the total shares available for equity awards to new hires under this Nasdaq-compliant plan up from prior registrations (May 2020 & May 2023) by incorporating those earlier S-8 statements.

The company is classified as a non-accelerated filer and smaller reporting company; therefore, the registration relies on simplified disclosure. No proceeds flow to the company—shares will be issued as restricted stock units or stock options to attract and retain talent. While the aggregate amount is modest (<2% of the 20.4 m shares outstanding at 30 Jun 2025), it adds minor dilution potential and increases equity-based compensation expense over time.